Lummy Strikes First Deal Under VC Fund Investment
This article was originally published in PharmAsia News
TVM Capital Life Science has established a new $50 million venture capital fund with investment from Chinese partner Lummy, which has already tapped the new vehicle for a licensing deal for an oncology dendritic vaccine.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.